LJPC La Jolla Pharmaceutical Company

28.18
0  0%
Previous Close 28.20
Open 28.13
Price To book 9.47
Market Cap 514.59M
Shares 18,261,000
Volume 286,465
Short Ratio 2.35
Av. Daily Volume 876,014

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Pivotal trial to be initiated in mid-2017.
LJPC-401
Beta thalassemia patients suffering from iron overload
Phase 3 data released February 27, 2016 - primary endpoint hit. Secondary endpoints not mentioned. NDA filing due 2H 2017.
LJPC-501
Catecholamine-resistant hypotension (CRH)

Latest News

  1. La Jolla Pharmaceutical posts 1Q loss
  2. La Jolla Pharmaceutical Company Announces Financial Results for the Three Months Ended March 31, 2017 and Recent Corporate Progress
  3. La Jolla Pharmaceutical Co. – Value Analysis (NASDAQ:LJPC) : April 24, 2017
  4. La Jolla Pharmaceutical Co. breached its 50 day moving average in a Bullish Manner : LJPC-US : April 21, 2017
  5. La Jolla Pharmaceutical Company Announces Pricing of Public Offering of Common Stock
  6. La Jolla Pharmaceutical Company Announces Proposed Underwritten Public Offering of Common Stock
  7. Biotechs Remain the Best Place For Stock Picking
  8. La Jolla Pharmaceutical (LJPC) is in Overbought Territory: What's Next?
  9. La Jolla Pharmaceutical Co. :LJPC-US: Earnings Analysis: Q4, 2016 By the Numbers : March 7, 2017
  10. Biotech Bounce Set to Pick Up Steam
  11. 6 Stocks on the Move With Unusual Volume
  12. Dow Continues Record Streak: Today's Research Reports on La Jolla Pharmaceutical and Advanced Micro Devices
  13. Blog Coverage La Jolla's Lead Product Candidate LJPC-501 Posts Positive Phase-III Trial Results
  14. La Jolla Pharma Leads Biotech Gains On Hearty Hypotension-Drug Trial
  15. La Jolla Blood Pressure Drug Did Well In Study
  16. How to Trade 7 Most-Active Stocks: AMD, La Jolla Pharma, Tesla and More
  17. How La Jolla’s Low Blood Pressure Treatment Is Driving New Highs
  18. Why La Jolla Pharmaceutical Company Shares Are Skyrocketing
  19. Stocks Trade Flat as Trump Pledges $54B Bump in Defense Spending
  20. Stock Futures Down, Quiet; Tesla Dips On Goldman Downgrade

SEC Filings

  1. 10-K/A (Amend) - Annual report (Section 13 and 15(d), not S-K Item 405) 17796452
  2. 10-Q - Quarterly report (Sections 13 or 15(d)) 17788996
  3. 8-K - Current report 17756646
  4. 8-K - Current report 17710877
  5. 424B5 - Prospectus (Rule 424(b)(5)) 17710872
  6. 424B2 - Prospectus (Rule 424(b)(2)) 17701531
  7. 8-K - Current report 17701509
  8. SC 13D/A (Amend) - General statement of acquisition of beneficial ownership 17667840
  9. 8-K - Current report 17649260
  10. 8-K - Current report 17633469